WO2020160617A1 - A membrane protein expression and distribution modulating composition and method of use thereof - Google Patents
A membrane protein expression and distribution modulating composition and method of use thereof Download PDFInfo
- Publication number
- WO2020160617A1 WO2020160617A1 PCT/AU2020/050092 AU2020050092W WO2020160617A1 WO 2020160617 A1 WO2020160617 A1 WO 2020160617A1 AU 2020050092 W AU2020050092 W AU 2020050092W WO 2020160617 A1 WO2020160617 A1 WO 2020160617A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- formulated
- extract
- administration
- sulphoraphane
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims abstract description 16
- 108010052285 Membrane Proteins Proteins 0.000 title description 4
- 102000018697 Membrane Proteins Human genes 0.000 title description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 25
- 108050004036 Klotho Proteins 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 24
- 102000015834 Klotho Human genes 0.000 claims abstract description 23
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 13
- 230000014616 translation Effects 0.000 claims abstract description 13
- 102000007469 Actins Human genes 0.000 claims abstract description 12
- 108010085238 Actins Proteins 0.000 claims abstract description 12
- 240000004385 Centaurea cyanus Species 0.000 claims abstract description 12
- 235000005940 Centaurea cyanus Nutrition 0.000 claims abstract description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 12
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims abstract description 12
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 12
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 12
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 12
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 12
- 229960002061 ergocalciferol Drugs 0.000 claims abstract description 12
- 229940094952 green tea extract Drugs 0.000 claims abstract description 12
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 12
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 12
- 239000011777 magnesium Substances 0.000 claims abstract description 12
- 235000001055 magnesium Nutrition 0.000 claims abstract description 12
- 229940091250 magnesium supplement Drugs 0.000 claims abstract description 12
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 12
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 12
- 229940016667 resveratrol Drugs 0.000 claims abstract description 12
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 12
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960005559 sulforaphane Drugs 0.000 claims abstract description 12
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims abstract description 12
- 235000001892 vitamin D2 Nutrition 0.000 claims abstract description 12
- 239000011653 vitamin D2 Substances 0.000 claims abstract description 12
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 12
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 12
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 12
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 12
- 239000011701 zinc Substances 0.000 claims abstract description 12
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 12
- 230000009467 reduction Effects 0.000 claims abstract description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 230000003111 delayed effect Effects 0.000 claims description 5
- 239000002702 enteric coating Substances 0.000 claims description 5
- 238000009505 enteric coating Methods 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000010410 layer Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 2
- 239000007916 tablet composition Substances 0.000 claims description 2
- 125000005591 trimellitate group Chemical group 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 230000032683 aging Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 230000018109 developmental process Effects 0.000 abstract description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
- 230000007170 pathology Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 206010048768 Dermatosis Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 102000003570 TRPV5 Human genes 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000003430 Mitral Valve Prolapse Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010058105 Neutrophilic dermatosis Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108050007112 Transient receptor potential cation channel subfamily V member 5 Proteins 0.000 description 1
- 101150034091 Trpv5 gene Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 208000021138 brain aneurysm Diseases 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- -1 i.e. Proteins 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1719—Muscle proteins, e.g. myosin or actin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present disclosure relates to a membrane protein expression and distribution modulating composition and a method of use thereof.
- compositions that will mitigate an effect of ageing when administered in a therapeutically effective dose to a subject in need thereof and a method of using such a composition.
- Dysfunctional protein production accumulates in multicellular organisms, such as humans, with the passage of time. Such dysfunction is associated with deleterious effects that are typically termed“ageing”. These deleterious effects, including a deterioration of cell function, lead to an increase of ageing-related pathologies and inevitably accelerate mortality. Increasing relevant protein production to physiologic levels may delay onset of ageing-related negative health effects and contribute to economic benefits, i.e., a reduction in healthcare costs.
- the present disclosure in one aspect sets forth a composition including a therapeutically effective dose of each of actin, a green tea extract, sulphoraphane, y- aminobutyric acid (GABA), an omega-3 fatty acid, a Cordyceps sinensis extract, zinc, a Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol, the composition formulated to mitigate a condition associated with a reduction in Klotho protein production and/or distribution of a subject.
- GABA y- aminobutyric acid
- the present disclosure in another aspect sets forth a method of modulating Klotho protein production and/or distribution, the method including administering to a subject in need thereof a composition including a therapeutically effective dose of each of actin, a green tea extract, sulphoraphane, y-aminobutyric acid (GABA), an omega- 3 fatty acid, a Cordyceps sinensis extract, zinc, a Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol.
- a composition including a therapeutically effective dose of each of actin, a green tea extract, sulphoraphane, y-aminobutyric acid (GABA), an omega- 3 fatty acid, a Cordyceps sinensis extract, zinc, a Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol.
- the present disclosure is directed to a composition that mitigates an effect of insufficient Klotho protein perse and/or reduced Klotho protein activity in one or more cell of a multicellular organism, such as humans, that may arise with the passage of time.
- the present disclosure also relates to a method of use of the composition.
- a composition for mitigating ageing-related pathologies of a subject includes a therapeutically effective dose of each of actin, a green tea extract, sulphoraphane, y-aminobutyric acid (GABA), an omega-3 fatty acid, a Cordyceps sinensis extract, zinc, a Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol, the composition formulated to mitigate a condition associated with reduced Klotho protein production and/or distribution of the subject.
- GABA y-aminobutyric acid
- a Cordyceps sinensis extract zinc
- a Centaurea cyanus extract cholecalciferol, ergocalciferol, magnesium, and resveratrol
- the amount of actin, green tea extract, sulphoraphane, g-aminobutyric acid (GABA), omega-3 fatty acid, a Cordyceps sinensis extract, zinc, Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol will depend on a preferred route of administration, the rate and expected duration of release of the composition, and the nature of the condition, disease or disorder to be treated or prevented.
- each of the actin, green tea extract, sulphoraphane, g-aminobutyric acid (GABA), an omega-3 fatty acid, the Cordyceps sinensis extract, zinc, the Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol may be present in an amount of 20 - 80 mg.
- each of the actin, green tea extract, sulphoraphane, y- aminobutyric acid (GABA), an omega-3 fatty acid, the Cordyceps sinensis extract, zinc, the Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol may be present in an amount of 40 mg.
- composition herein disclosed may be delivered to a subject in need thereof by any one of several routes.
- the composition may be delivered via buccal, infusion (e.g., a bolus infusion), inhalation, intracranial injection, enteral, intradermal, intramuscular, intranasal, intraocular, intraperitoneally, intravenously, orally, rectal, rectal, subcutaneously, sublingual, topically, transdermal, vaginal, or any combination thereof.
- the composition may be formulated for enteral administration.
- composition herein disclosed may be formulated for delayed release (also termed sustained or slow release, timed release, delayed release, or controlled release).
- delayed release also termed sustained or slow release, timed release, delayed release, or controlled release.
- Such compositions may generally be prepared using well known technology and administered by, for example, oral, rectal, intradermal, or subcutaneous implantation, or by implantation at the desired target site in a delayed release manner.
- Delayed-release formulations may contain the compound dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling barrier.
- a particularly preferred embodiment of the composition may be formulated in an enteric coating layer.
- the enteric coating layer may include one or more of cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, and water-based polymer solutions or dispersions of acrylates.
- composition disclosed herein may be formulated with a buffering agent to protect the compound from low pH of the gastric environment and/or an enteric coating.
- the composition may, when administer orally, buccally, or sublingually, may be formulated with a flavouring agent, e.g., in a liquid, solid or semi-solid formulation.
- Preferred embodiments may include one or more pharmaceutically acceptable dispersant, excipient, pH-buffering compound, and pigment.
- Preferred embodiments will include at least one excipient that is biocompatible and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release.
- the excipient facilitates absorption. In yet a further particularly preferred embodiment, the excipient enhances solubility.
- the composition may be a tablet formulation.
- the composition may be a powder formulation.
- the powder formulation may be in a capsule.
- the composition may be a liquid formulation.
- the composition may be formulated for parenteral administration.
- the composition may be formulated for subcutaneous administration.
- the composition may be formulated for intramuscular administration.
- the composition may be formulated for intravenous administration.
- the composition may be formulated for intradermal administration.
- the composition may be formulated for transdermal administration.
- composition disclosed herein will be administered for a sufficient amount of time to selectively modulate Klotho protein production and/or distribution.
- modulation may be associated with transcription of the Klotho gene, i.e., HTFC3, maturation of a Klotho mRNA transcript, transport of a mature Klotho mRNA transcript into the cytoplasm, docking of a mature Klotho mRNA transcript with one or more ribosome, translation of a mature Klotho transcript, post-translational modification of a Klotho protein, transport of a Klotho protein to a membrane location, docking of a mature Klotho protein in a organelle and/or cell membrane, insertion of a mature Klotho protein as an integral membrane protein, and a reduction in Klotho degradation.
- Klotho as a transmembrane protein related to b-glucuronidases.
- a reduction in Klotho protein, potentially production, concentration, and or distribution may ameliorate at least one symptom associated with a number of pathologies.
- pathologies may include age-related loss of pulmonary function, Alzheimer's disease, angina, aortic aneurysm, arrhythmia, arteriosclerosis, asthma, atherosclerosis, atopic dermatitis, brain aneurysm, bronchiectasis, cardiac diastolic dysfunction, a cancer, cardiac fibrosis, cardiac stress resistance, cardiomyopathy, carotid artery disease, cataracts, chronic obstructive pulmonary disease, chronic renal failure, congestive heart failure, coronary artery disease, coronary thrombosis, cutaneous lupus, cutaneous lymphomas, cystic fibrosis, dementia, diabetes, diabetic ulcer, diseases and disorders related to photosensitivity or photoaging, dysesthesia, eczema, eczematous eruptions, emphysema,
- composition will be administered for a time sufficient and in an amount sufficient that selectively ameliorates at least one symptom associated with insufficient Klotho production and/or distribution as a functional integral protein in an organelle and/or cell membrane.
- a method for modulating Klotho protein production and/or distribution includes administering to a subject in need thereof a composition including a therapeutically effective dose of each of actin, a green tea extract, sulphoraphane, y-aminobutyric acid (GABA), an omega-3 fatty acid, a Cordyceps sinensis extract, zinc, a Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol.
- the method may include a treatment course no longer than (a) one month, or (b) no longer than two months, or (c) no longer than three months.
- each treatment course is no longer than (a) five days, (b) seven days, (c) ten days, (d) fourteen days, or (e) twenty-one days.
- the composition is administered every second day or every third day of each treatment course.
- the composition is administered once daily during each treatment course.
- the composition is administered twice daily during each treatment course. Suitable interval periods between treatments will be known to a person skilled in the art.
- the subject may be a multicellular animal.
- the multicellular animal is a human.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Dysfunctional protein production is associated with the development of morbidities related to tissue damage that accumulates with age and a need exists for a composition that will mitigate an effect of ageing when administered in a therapeutically effective dose to a subject in need thereof and a method of using such a composition. Provided is a composition including a therapeutically effective dose of each of actin, a green tea extract, sulphoraphane, γ-aminobutyric acid (GABA), an omega-3 fatty acid, a Cordyceps sinensis extract, zinc, a Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol, the composition formulated to mitigate a condition associated with a reduction in Klotho protein production and/or distribution of a subject and a method of use thereof.
Description
A MEMBRANE PROTEIN EXPRESSION AND DISTRIBUTION MODULATING COMPOSITION AND METHOD OF USE THEREOF
Field of Invention
The present disclosure relates to a membrane protein expression and distribution modulating composition and a method of use thereof.
Background of Invention
As animals, including humans, age, a reduction in the production of important proteins leads to accumulated damage in the tissues. Such damage is thought to be associated with age-related dysfunction of the cells. Indeed, dysfunctional protein production is associated with the development of morbidities within the ageing populations world-wide.
Given the afore-mentioned dysfunction and morbidities within the ageing populations around the world, a need exists for a composition that will mitigate an effect of ageing when administered in a therapeutically effective dose to a subject in need thereof and a method of using such a composition.
Summary
Dysfunctional protein production accumulates in multicellular organisms, such as humans, with the passage of time. Such dysfunction is associated with deleterious effects that are typically termed“ageing”. These deleterious effects, including a deterioration of cell function, lead to an increase of ageing-related pathologies and inevitably accelerate mortality. Increasing relevant protein production to physiologic levels may delay onset of ageing-related negative health effects and contribute to economic benefits, i.e., a reduction in healthcare costs.
The present disclosure in one aspect sets forth a composition including a therapeutically effective dose of each of actin, a green tea extract, sulphoraphane, y- aminobutyric acid (GABA), an omega-3 fatty acid, a Cordyceps sinensis extract, zinc, a Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol, the composition formulated to mitigate a condition associated with a reduction in Klotho protein production and/or distribution of a subject.
The present disclosure in another aspect sets forth a method of modulating Klotho protein production and/or distribution, the method including administering to a subject in need thereof a composition including a therapeutically effective dose of each of actin, a green tea extract, sulphoraphane, y-aminobutyric acid (GABA), an omega-
3 fatty acid, a Cordyceps sinensis extract, zinc, a Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol.
The reference to any prior art in this specification is not and should not be taken as an acknowledgement or any form of suggestion that the prior art forms part of the common general knowledge in Australia or in any other country.
It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed, unless otherwise stated. In the present specification and claims, the word“comprising” and its derivatives including“comprises” and“comprise” include each of the stated integers but does not exclude the inclusion of one or more integers. The claims as filed with this application are hereby incorporated by reference in the description.
Detailed Description
The present disclosure is directed to a composition that mitigates an effect of insufficient Klotho protein perse and/or reduced Klotho protein activity in one or more cell of a multicellular organism, such as humans, that may arise with the passage of time. The present disclosure also relates to a method of use of the composition.
In a preferred embodiment, a composition for mitigating ageing-related pathologies of a subject includes a therapeutically effective dose of each of actin, a green tea extract, sulphoraphane, y-aminobutyric acid (GABA), an omega-3 fatty acid, a Cordyceps sinensis extract, zinc, a Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol, the composition formulated to mitigate a condition associated with reduced Klotho protein production and/or distribution of the subject. A skilled person will appreciate that the reduction in this context is expressed relative to a healthy subject. Without wishing to be bound by theory, a therapeutically effective dose refers to an amount of a composition administered to a subject, either as a single dose or as part of a series of doses, which is effective to produce a desired therapeutic effect.
It will be appreciated that the amount of actin, green tea extract, sulphoraphane, g-aminobutyric acid (GABA), omega-3 fatty acid, a Cordyceps sinensis extract, zinc, Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol will depend on a preferred route of administration, the rate and expected duration of release of the composition, and the nature of the condition, disease or disorder to be treated or prevented. In a preferred embodiment, each of the actin, green tea extract,
sulphoraphane, g-aminobutyric acid (GABA), an omega-3 fatty acid, the Cordyceps sinensis extract, zinc, the Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol may be present in an amount of 20 - 80 mg. In a further preferred embodiment, each of the actin, green tea extract, sulphoraphane, y- aminobutyric acid (GABA), an omega-3 fatty acid, the Cordyceps sinensis extract, zinc, the Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol may be present in an amount of 40 mg.
A person skilled in the art will appreciate that the composition herein disclosed may be delivered to a subject in need thereof by any one of several routes. By way of non-limiting example, the composition may be delivered via buccal, infusion (e.g., a bolus infusion), inhalation, intracranial injection, enteral, intradermal, intramuscular, intranasal, intraocular, intraperitoneally, intravenously, orally, rectal, rectal, subcutaneously, sublingual, topically, transdermal, vaginal, or any combination thereof. Preferably, the composition may be formulated for enteral administration.
It will be appreciated that the composition herein disclosed may be formulated for delayed release (also termed sustained or slow release, timed release, delayed release, or controlled release). Such compositions may generally be prepared using well known technology and administered by, for example, oral, rectal, intradermal, or subcutaneous implantation, or by implantation at the desired target site in a delayed release manner. Delayed-release formulations may contain the compound dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling barrier.
A particularly preferred embodiment of the composition may be formulated in an enteric coating layer. In a preferred embodiment, the enteric coating layer may include one or more of cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, and water-based polymer solutions or dispersions of acrylates.
A skilled person will appreciate that the composition disclosed herein may be formulated with a buffering agent to protect the compound from low pH of the gastric environment and/or an enteric coating. Furthermore, the composition may, when administer orally, buccally, or sublingually, may be formulated with a flavouring agent, e.g., in a liquid, solid or semi-solid formulation. Preferred embodiments may include one or more pharmaceutically acceptable dispersant, excipient, pH-buffering
compound, and pigment. Preferred embodiments will include at least one excipient that is biocompatible and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release.
In a particularly preferred embodiment, the excipient facilitates absorption. In yet a further particularly preferred embodiment, the excipient enhances solubility.
In a further preferred embodiment, the composition may be a tablet formulation.
In a further preferred embodiment, the composition may be a powder formulation. In a particularly preferred embodiment, the powder formulation may be in a capsule.
In a further preferred embodiment, the composition may be a liquid formulation. Preferably, the composition may be formulated for parenteral administration. In a particularly preferred embodiment, the composition may be formulated for subcutaneous administration. In a further particularly preferred embodiment, the composition may be formulated for intramuscular administration. In a further particularly preferred embodiment, the composition may be formulated for intravenous administration. In a further particularly preferred embodiment, the composition may be formulated for intradermal administration. In a further particularly preferred embodiment, the composition may be formulated for transdermal administration.
A skilled person will appreciate that the composition disclosed herein will be administered for a sufficient amount of time to selectively modulate Klotho protein production and/or distribution. Such modulation may be associated with transcription of the Klotho gene, i.e., HTFC3, maturation of a Klotho mRNA transcript, transport of a mature Klotho mRNA transcript into the cytoplasm, docking of a mature Klotho mRNA transcript with one or more ribosome, translation of a mature Klotho transcript, post-translational modification of a Klotho protein, transport of a Klotho protein to a membrane location, docking of a mature Klotho protein in a organelle and/or cell membrane, insertion of a mature Klotho protein as an integral membrane protein, and a reduction in Klotho degradation. A person skilled in the art will recognise Klotho as a transmembrane protein related to b-glucuronidases.
A skilled person will also appreciated that a reduction in Klotho protein, potentially production, concentration, and or distribution, may ameliorate at least one symptom associated with a number of pathologies. Such pathologies may include age-related loss of pulmonary function, Alzheimer's disease, angina, aortic aneurysm, arrhythmia, arteriosclerosis, asthma, atherosclerosis, atopic dermatitis, brain
aneurysm, bronchiectasis, cardiac diastolic dysfunction, a cancer, cardiac fibrosis, cardiac stress resistance, cardiomyopathy, carotid artery disease, cataracts, chronic obstructive pulmonary disease, chronic renal failure, congestive heart failure, coronary artery disease, coronary thrombosis, cutaneous lupus, cutaneous lymphomas, cystic fibrosis, dementia, diabetes, diabetic ulcer, diseases and disorders related to photosensitivity or photoaging, dysesthesia, eczema, eczematous eruptions, emphysema, endocarditis, eosinophilic dermatosis, fibrohistocytic proliferations of skin, frailty, glaucoma, hearing loss, herniated intervertebral disc, Huntington's disease, hypercholesterolemia, hyperlipidemia, hyperpigmentation, hypertension, hypertension, immunobullous dermatosis, impaired angiogenesis, impaired endothelium-dependent vasodilation, inflammatory bowel disease, klotho-associated vitamin D metabolic abnormalities, kyphosis, liver fibrosis, macular degeneration, metabolic syndrome, mild cognitive impairment, mitral valve prolapse, motor neuron dysfunction, muscle fatigue, myocardial infarction, nevi, rashes, obesity, oral mucositis, oral submucosa fibrosis, osteoarthritis, osteoarthritis, osteoporosis, osteoporosis, pathologies associated with the cardiovascular system through endothelium-derived NO production, pancreatic fibrosis, Parkinson's disease, pathologies associated with cellular calcium homeostasis, pathologies associated with perturbed TRPV5, i.e., transient receptor potential cation channel subfamily v member 5, pathologies of the skin, pemphigoid, pemphigus, peripheral vascular disease, presbyopia, pruritis, psoriasis, pulmonary fibrosis, pulmonary fibrosis, reactive neutrophilic dermatosis, renal disease, renal failure, rhytides, sarcopenia, skin conditions, skin wound healing, stroke, urticaria, and vision loss.
As described herein it will be appreciated that the composition will be administered for a time sufficient and in an amount sufficient that selectively ameliorates at least one symptom associated with insufficient Klotho production and/or distribution as a functional integral protein in an organelle and/or cell membrane.
In another embodiment, a method for modulating Klotho protein production and/or distribution, the method includes administering to a subject in need thereof a composition including a therapeutically effective dose of each of actin, a green tea extract, sulphoraphane, y-aminobutyric acid (GABA), an omega-3 fatty acid, a Cordyceps sinensis extract, zinc, a Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol.
In preferred embodiments of the method disclosed herein, the method may include a treatment course no longer than (a) one month, or (b) no longer than two months, or (c) no longer than three months. In further preferred embodiments, each treatment course is no longer than (a) five days, (b) seven days, (c) ten days, (d) fourteen days, or (e) twenty-one days. In further preferred embodiments, the composition is administered every second day or every third day of each treatment course. In another specific embodiment, the composition is administered once daily during each treatment course. In another preferred embodiment, the composition is administered twice daily during each treatment course. Suitable interval periods between treatments will be known to a person skilled in the art.
In a preferred embodiment, the subject may be a multicellular animal. Preferably, the multicellular animal is a human.
The features described with respect to one embodiment may be applied to other embodiments, or combined with, or interchanged with, the features of other embodiments without departing from the scope of the present invention.
Other embodiments of the disclosure will be apparent to those skilled in the art from consideration of the specification and practice of the disclosure disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the disclosure being indicated by the following claims.
Claims
1 . A composition comprising a therapeutically effective dose of each of actin, a green tea extract, sulphoraphane, y-aminobutyric acid (GABA), an omega-3 fatty acid, a Cordyceps sinensis extract, zinc, a Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol, the composition formulated to mitigate a condition associated with a reduction in Klotho protein production and/or distribution of a subject.
2. The composition of claim 1 , wherein each of the actin, green tea extract, sulphoraphane, g-aminobutyric acid (GABA), an omega-3 fatty acid, the Cordyceps sinensis extract, zinc, the Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol is present in an amount of 20 - 80 mg.
3. The composition of either claim 1 or claim 2, wherein each of the actin, green tea extract, sulphoraphane, g-aminobutyric acid (GABA), an omega-3 fatty acid, the Cordyceps sinensis extract, zinc, the Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol is present in an amount of 40 mg.
4. The composition of any one of claims 1 to 3, formulated for enteral administration.
5. The composition of claim 4, formulated for delayed release.
6. The composition of claim 5, formulated in an enteric coating layer.
7. The composition of claim 6, wherein the enteric coating layer includes one or more of cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, and water-based polymer solutions or dispersions of acrylates.
8. The composition of any one of claims 1 to 7, further comprising one or more pharmaceutically acceptable dispersant, excipient, pH-buffering compound, and pigment.
9. The composition of claim 8, wherein the excipient facilitates absorption.
10. The composition of claim 8, wherein the excipient enhances solubility.
1 1 . The composition of any one of claims 1 to 10, wherein the composition is a tablet formulation.
12. The composition of any one of claims 1 to 10, wherein the composition is a powder formulation.
13. The composition of claim 12, wherein the powder formulation is in a capsule.
14. The composition of any one of claims 1 to 10, wherein the composition is a liquid formulation.
15. The composition of any one of claims 1 to 10 and 13, formulated for parenteral administration.
16. The composition of claim 15, formulated for subcutaneous administration.
17. The composition of claim 15, formulated for intramuscular administration.
18. The composition of claim 15, formulated for intravenous administration.
19. The composition of claim 15, formulated for intradermal administration.
20. The composition of claim 15, formulated for transdermal administration.
21 . A method of modulating Klotho protein production and/or distribution, the method comprising administering to a subject in need thereof a composition comprising a therapeutically effective dose of each of actin, a green tea extract, sulphoraphane, y-aminobutyric acid (GABA), an omega-3 fatty acid, a Cordyceps
sinensis extract, zinc, a Centaurea cyanus extract, cholecalciferol, ergocalciferol, magnesium, and resveratrol.
22. The method of claim 21 , wherein the subject is a human.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019900344A AU2019900344A0 (en) | 2019-02-05 | A membrane protein expression and distribution modulating composition and method of use thereof | |
| AU2019900344 | 2019-02-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2020160617A1 true WO2020160617A1 (en) | 2020-08-13 |
Family
ID=71946954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/AU2020/050092 WO2020160617A1 (en) | 2019-02-05 | 2020-02-05 | A membrane protein expression and distribution modulating composition and method of use thereof |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2020160617A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112915192A (en) * | 2021-03-05 | 2021-06-08 | 南方医科大学南方医院 | Application of KP-1 in preparation of medicine for treating chronic liver diseases |
| WO2021214188A1 (en) * | 2020-04-23 | 2021-10-28 | Vio Chemicals Ag | Compositions for stabilizing an isothiocyanate |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010065567A2 (en) * | 2008-12-01 | 2010-06-10 | Lifespan Extension Llc | Methods and compositions for altering health, wellbeing, and lifespan |
| US20130273175A1 (en) * | 2012-04-15 | 2013-10-17 | Jahahreeh Finley | Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation |
| WO2017210607A1 (en) * | 2016-06-02 | 2017-12-07 | Klotho Therapeutics, Inc. | Therapeutic recombinant klotho proteins and compositions and methods involving the same |
| WO2019113373A2 (en) * | 2017-12-06 | 2019-06-13 | Klotho Therapeutics, Inc. | Products and methods for assessing and increasing klotho protein levels |
-
2020
- 2020-02-05 WO PCT/AU2020/050092 patent/WO2020160617A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010065567A2 (en) * | 2008-12-01 | 2010-06-10 | Lifespan Extension Llc | Methods and compositions for altering health, wellbeing, and lifespan |
| US20130273175A1 (en) * | 2012-04-15 | 2013-10-17 | Jahahreeh Finley | Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation |
| WO2017210607A1 (en) * | 2016-06-02 | 2017-12-07 | Klotho Therapeutics, Inc. | Therapeutic recombinant klotho proteins and compositions and methods involving the same |
| WO2019113373A2 (en) * | 2017-12-06 | 2019-06-13 | Klotho Therapeutics, Inc. | Products and methods for assessing and increasing klotho protein levels |
Non-Patent Citations (1)
| Title |
|---|
| KLOTHO: BECOME SMARTER AND LIVE LONGER WITH 50+ WAYS TO INCREASE KLOTHO, 23 January 2019 (2019-01-23), XP055731570, Retrieved from the Internet <URL:https://web.archive.org/web/20190123063736/https://mybiohack.com/blog/longevity-intelligence-klotho-genetics-fat-vitamin> [retrieved on 20200320] * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021214188A1 (en) * | 2020-04-23 | 2021-10-28 | Vio Chemicals Ag | Compositions for stabilizing an isothiocyanate |
| CN112915192A (en) * | 2021-03-05 | 2021-06-08 | 南方医科大学南方医院 | Application of KP-1 in preparation of medicine for treating chronic liver diseases |
| CN112915192B (en) * | 2021-03-05 | 2022-10-25 | 南方医科大学南方医院 | Application of KP-1 in preparation of medicine for treating chronic liver diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2376077T3 (en) | Preparation and method of treating diabetes | |
| WO2020160617A1 (en) | A membrane protein expression and distribution modulating composition and method of use thereof | |
| Kaplan et al. | Impaired renal autoregulation: implications for the genesis of hypertension and hypertension-induced renal injury | |
| RU2016129266A (en) | COMPOSITIONS AND METHODS OF TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASE | |
| JP5810166B2 (en) | Prophylactic / therapeutic agent for diabetic cardiovascular complications | |
| JP2019142925A (en) | Composition and method for treatment of diabetes | |
| US10570083B2 (en) | Compositions comprising oxo-derivatives of fatty acids and methods of making and using same | |
| ES2729862T3 (en) | Saffron-based compositions for the prevention and / or treatment of degenerative eye disorders | |
| Guarnieri et al. | Fighting protein-energy wasting in chronic kidney disease: a challenge of complexity | |
| WO2020160619A1 (en) | A glycation reducing composition and method of use thereof | |
| US20210052703A1 (en) | Glp-1 composition for treating obesity and weight management | |
| WO2020160618A1 (en) | An anti-cell-senescence composition and method of use | |
| WO2020160620A1 (en) | An epigenetic drift attenuating composition and method of use thereof | |
| JP2017095510A (en) | Short-acting dihydropyridine (clevidipine) for use in reducing stroke damage | |
| EP2948142B1 (en) | Combinations with 2-aminoethanesulfonic acid | |
| US10925849B2 (en) | Method of treatment of obesity | |
| EP3796901A2 (en) | Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease | |
| US12023313B2 (en) | Method of treatment of obesity | |
| JP6510019B2 (en) | Compounds of activated AMPK and uses thereof | |
| US20220387305A1 (en) | Composition and method for treatment of diabetes | |
| US20150224081A1 (en) | Composition and method for treatment of diabetes | |
| US20150290164A1 (en) | Sulforaphane for Treating or Reducing Insulin Resistance of the Liver | |
| RU2219923C2 (en) | Method for preventing postoperative disorders of myocardial function in cardiosurgical patients at background of progressing hypothyroidism accompanied by activation of peroxide metabolism | |
| US20210085627A1 (en) | Methods of treating diseases and disorders using compositions comprising 18-hepe, 12-hepe, or combinations thereof | |
| KR20210070920A (en) | Composition for suppressing appetite or preventing or improving obesity comprising ascorbic acid or metabolites thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20752591 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20752591 Country of ref document: EP Kind code of ref document: A1 |